AHA 2023 | Use of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Subclinical atrial fibrillation (AF), generally asymptomatic and of short duration, often requires continuous long-term monitoring using pacemakers or defibrillators for its detection. While subclinical AF is linked to an increased risk of stroke, the usefulness of oral anticoagulation as a treatment remains uncertain.

AHA 2023 | ORBITA-2: Angioplastia coronaria vs placebo en angina estable para la reducción de síntomas

In a double-blind randomized trial, one group received apixaban and the other received aspirin. The primary efficacy endpoint was the rate of systemic embolism or stroke (SE), while the primary safety endpoint focused on the rate of major bleeding.

The sample included 4012 patients with an average age of 76 years and an average CHA2DS2-VASc score of 3.9. Of them, 36% were women. In terms of the primary efficacy endpoint, the incidence in the apixaban group was 0.78%, compared with 1.24% in the aspirin group (hazard ratio [HR]: 0.63; 95% confidence interval [CI]: 0.45-0.88; P=0.007). The rate of major bleeding was 1.71% in the apixaban group and 0.94% in the aspirin group (HR: 1.8; 95% CI: 1.26-2.57; P=0.001).

Conclusion

Among patients with subclinical AF, the use of apixaban led to a lower risk of systemic embolism or stroke compared with aspirin, although it was also associated with an increased risk of major bleeding.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.

Reference: Jeff S. Healey, M.D et al. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...